Efficacy and Safety of FEIBA Prophylaxis Evaluation in Young Patients With Haemophilia and High Titer Inhibitor

被引：0
|
作者：
Karimi, M. [1 ]
Tavoosi, H. [1 ]
Haghpanah, S. [1 ]
Ardeshiri, R. [1 ]
Zarei, T. [1 ]
机构：
[1] Shiraz Univ Med Sci, Hematol Res Ctr, Shiraz, Iran
来源：
HAEMOPHILIA | 2015年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PP049
引用
收藏
页码：42 / 42
页数：1
相关论文
共 50 条
  • [31] Evaluation of EC50 of factor VIII as predictor of prophylaxis efficacy in patients with severe haemophilia A
    Fernandez-Bello, I
    Rode, F.
    Alvarez-Roman, M. T.
    Butta, N., V
    Rivas-Munoz, S.
    Hernandez-Moreno, A. L.
    de la Corte-Rodriguez, H.
    Martin-Salces, M.
    Larsen, L. F.
    Jimenez-Yuste, V
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2019, 128 : 215 - 221
  • [32] HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH HAEMOPHILIA AND INHIBITORS ON PROPHYLAXIS WITH ANTI-INHIBITOR COMPLEX CONCENTRATE: RESULTS FROM THE PRO-FEIBA STUDY
    Gringeri, A.
    Leissinger, C.
    Cortesi, P. A.
    Fusco, F.
    Riva, S.
    Mantovani, L. G.
    VALUE IN HEALTH, 2012, 15 (07) : A332 - A332
  • [33] Evaluation of Safety and Efficacy of Emicizumab Prophylaxis in Egyptian Pediatric Patients with Hemophilia A
    Hassan, Tamer
    Zakaria, Marwa
    Fathy, Manar
    Farag, Ahmed
    Abdelhady, Eman
    Gameil, Dalia
    Abu Hashem, Mustafa
    TURKISH JOURNAL OF HEMATOLOGY, 2024, 41 (04) : 256 - 263
  • [34] A transient high titer inhibitor in a boy with severe haemophilia A treated with recombinant factor VIII
    Gottstein, S.
    Budde, U.
    Klamroth, R.
    HAMOSTASEOLOGIE, 2009, 29 : S61 - S61
  • [35] Health-related quality of life in patients with haemophilia and inhibitors on prophylaxis with anti-inhibitor complex concentrate: results from the Pro-FEIBA study
    Gringeri, A.
    Leissinger, C.
    Cortesi, P. A.
    Jo, H.
    Fusco, F.
    Riva, S.
    Antmen, B.
    Berntorp, E.
    Biasoli, C.
    Carpenter, S.
    Kavakli, K.
    Morfini, M.
    Negrier, C.
    Rocino, A.
    Schramm, W.
    Windyga, J.
    Zulfikar, B.
    Mantovani, L. G.
    HAEMOPHILIA, 2013, 19 (05) : 736 - 743
  • [36] CHALLENGES IN TREATMENT MONITORING OF SEVERE HAEMOPHILIA PATIENTS WITH HIGH TITER INHIBITORS
    Ursu, C. E.
    Poenaru, D. V.
    Patrascu, J. M.
    Boia, E.
    Arghirescu, S.
    Savescu, D.
    Cernat, L.
    Boeriu, E.
    Jinca, C.
    Serban, M.
    HAEMOPHILIA, 2020, 26 : 30 - 31
  • [37] Eight years of pharmacovigilance evaluation with ReFacto® -: safety and efficacy in previously untreated haemophilia A patients
    Pollmann, H.
    HAEMOPHILIA, 2008, 14 : 52 - 52
  • [38] First report of emicizumab use in a patient with severe haemophilia A and high-titer inhibitor in Uruguay
    Berro, Maximiliano
    Insagaray, Juan
    Rodriguez, Ismael
    ANALES DE LA FACULTAD DE MEDICINA-UNIVERSIDAD DE LA REPUBLICA URUGUAY, 2020, 7 (02):
  • [39] SUBCUTANEOUS CONCIZUMAB PROPHYLAXIS IN PATIENTS WITH HAEMOPHILIA A OR B WITH INHIBITORS: EFFICACY AND SAFETY RESULTS BY HAEMOPHILIA SUBTYPE FROM THE PHASE 3 EXPLORER7 TRIAL
    Mathias, M.
    Cepo, K.
    d'Oiron, R.
    Frei-Jones, M.
    Goh, A. -S.
    Odgaard-Jensen, J.
    HAEMOPHILIA, 2023, 29 : 17 - 17
  • [40] Evaluation of pharmacokinetics, efficacy and safety of Immunate® solvent detergent in previously treated patients with severe haemophilia A
    Nemes, L.
    Lissitchkov, T.
    Klukowska, A.
    Dobaczewski, G.
    Komrska, V.
    Zimmermann, R.
    Auerswald, G.
    Engl, W.
    Pavlova, B.
    Abbuehl, B.
    Ehrilch, H. J.
    HAEMOPHILIA, 2007, 13 (01) : 9 - 11
12345